Cited by 485PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAutophagy in Disease and Therapy

The DOI matches its Crossref record; 228 of the 234 references it cites were found in a registry or an index.

mTOR: Role in cancer, metastasis and drug resistance

Murugan, Avaniyapuram Kannan·2019·Seminars in Cancer Biology

DOI 10.1016/j.semcancer.2019.07.003

Open this paper in CoChat — free account

Abstract

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that gets inputs from the amino acids, nutrients, growth factor, and environmental cues to regulate varieties of fundamental cellular processes which include protein synthesis, growth, metabolism, aging, regeneration, autophagy, etc. The mTOR is frequently deregulated in human cancer and activating somatic mutations of mTOR were recently identified in several types of human cancer and hence mTOR is therapeutically targeted. mTOR inhibitors were commonly used as immunosuppressors and currently, it is approved for the treatment of human malignancies. This review briefly focuses on the structure and biological functions of mTOR. It extensively discusses the genetic deregulation of mTOR including amplifications and somatic mutations, mTOR-mediated cell growth promoting signaling, therapeutic targeting of mTOR and the mechanisms of resistance, the role of mTOR in precision medicine and other recent advances in further understanding the role of mTOR in cancer.

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2019.07.003

Cites

228 of 228 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway
Zhou, X.-M., Sun, R., Luo, D., Sun, J., Zhang, M.-Y., Wang, M.-H., Yang, Y., Wang, H., & Mai, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7215 · Cited by 66
Retracted
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Rho GTPases and the Actin Cytoskeleton
Hall, A. (1998) · Science · doi:10.1126/science.279.5350.509 · Cited by 6,138
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Flagged first, then by citations

Show all 234 references

6 of the 234 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Davies, 2005, Somatic mutations of the protein kinase gene family in human lung cancer, Cancer Res., 65, 7591, 10.1158/0008-5472.CAN-05-1855 · DOI
Sato, 2010, Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer, Oncogene, 29, 2746, 10.1038/onc.2010.28 · DOI

Sorted by citations

Items 201–300 of 485

Bisdemethoxycurcumin Promotes Apoptosis and Inhibits the Epithelial–Mesenchymal Transition through the Inhibition of the G-Protein-Coupled Receptor 161/Mammalian Target of Rapamycin Signaling Pathway in Triple Negative Breast Cancer Cells
Chou, C., Wang, H., Lin, Y., Tsai, D.-H., Lu, M., Ho, C., Hseu, Y., Yang, H., & Way, T. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05585 · Cited by 12
Endogenous Aβ induces osteoporosis through an mTOR-dependent inhibition of autophagy in bone marrow mesenchymal stem cells (BMSCs)
Lin, Y., Chen, T., Chen, J., Fang, Y., & Zeng, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-6427 · Cited by 11
A Ductal-Cell-Related Risk Model Integrating Single-Cell and Bulk Sequencing Data Predicts the Prognosis of Patients With Pancreatic Adenocarcinoma
Wang, X., Dou, X., Ren, X., Rong, Z., Sun, L., Deng, Y., Chen, P., & Li, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.763636 · Cited by 11
Design, synthesis and biological evaluation of novel 9-methyl-9H-purine and thieno[3, 2-d]pyrimidine derivatives as potent mTOR inhibitors
Yang, Y.-Y., Wang, W., Hu, X.-T., Chen, X., Ni, Y., Lei, Y.-H., Qiu, Q.-Y., Tao, L.-Y., Luo, T.-W., & Wang, N. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106356 · Cited by 10
Network pharmacology and molecular docking analysis on Shenfu Qiangxin indicate mTOR is a potential target to treat heart failure
Zou, P., Li, J., Zhang, Y., Qian, Z., Nie, H., Yang, N. C., Zhang, L., Li, L., Peng, D., & Zhang, C. (2024) · European journal of medical research · doi:10.1186/s40001-024-01732-8 · Cited by 10
Targeting NPM1 inhibits proliferation and promotes apoptosis of hepatic progenitor cells via suppression of mTOR signalling pathway
Wang, P., Wang, M., Liu, L., Li, H., Liu, H., Ren, J., Liu, T., Cong, M., Zhu, Z., Zhao, X., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03898-8 · Cited by 10
mTOR Variants Activation Discovers PI3K-like Cryptic Pocket, Expanding Allosteric, Mutant-Selective Inhibitor Designs
Liu, Y., Zhang, W., Jang, H., & Nussinov, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02022 · Cited by 10
Rapamycin ameliorates senescence of periodontal ligament stem cells and promotes their osteogenesis via the PI3K/AKT pathway
Zheng, Z., Li, Z., Liu, X., Liu, L., Ping, Z., Cui, Y., & Ding, G. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114517 · Cited by 11
QKI-induced circ_0001766 inhibits colorectal cancer progression and rapamycin resistance by miR-1203/PPP1R3C/mTOR/Myc axis
Zhou, Y., Gao, Y., Peng, Y., Cai, C., Han, Y., Chen, Y., Deng, G., Ouyang, Y., Shen, H., Zeng, S., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02478-w · Cited by 11
Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation
Lelong, E. I. J., Khelifi, G., Adjibade, P., Joncas, F., St-Sauveur, V. G., Paquette, V., Gris, T., Zoubeidi, A., Audet‐Walsh, É., Lambert, J., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac034 · Cited by 14
Effect of condylar chondrocyte exosomes on condylar cartilage osteogenesis in rats under tensile stress
Shi, Y., Shao, J., Zhang, Z., Zhang, J., & Lu, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1061855 · Cited by 10
HDAC6 Negatively Regulates miR-155-5p Expression to Elicit Proliferation by Targeting RHEB in Microvascular Endothelial Cells under Mechanical Unloading
Xu, L., Zhang, L., Zhang, X., Li, G., Wang, Y., Dong, J., Wang, H., Hu, Z., Cao, X., Zhang, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910527 · Cited by 10
Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment
Yadav, M., Uikey, B. N., Rathore, S. S., Gupta, P. S., Kashyap, D., Kumar, C., Shukla, D., Vijayamahantesh, V., Chandel, A. K. S., Ahirwar, B., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1235711 · Cited by 9
A bibliometric analysis of the application of the PI3K-AKT-mTOR signaling pathway in cancer
Deng, Z., Qing, Q., & Huang, B. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03112-9 · Cited by 10
Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy
Liu, A.-B., Liu, J., Wang, S., Ма, Л., & Zhang, J. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03355-9 · Cited by 9
Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation
Lu, W., Yang, Z., Wang, M., Zhang, Y., Qi, Z., & Yang, X. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s460575 · Cited by 9
Tuberous Sclerosis Complex: New Insights into Pathogenesis and Therapeutic Breakthroughs
Jurca, A. A., Jurcă, A. D., Petcheși, C. D., Bembea, D., Jurca, C. M., Severin, E. M., Jurca, S., & Vesa, C. M. (2025) · Life · doi:10.3390/life15030368 · Cited by 9
Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities
Li, J., Huang, Y., Li, J., Shi, M., Xiao, Y., Du, F., & Hu, G. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02578-w · Cited by 10
Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance
Che, X., Qi, X., Xu, Y., Wang, Q., & Wu, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6613151 · Cited by 9
Potential Therapeutic Targets in Ovarian Cancer: Autophagy and Metabolism
Park, M., Choe, S., Shin, M., Kim, A., Mo, K., Kwon, H., & Yoon, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2803047 · Cited by 9
The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
Ridwansyah, H., Wijaya, I., Bashari, M. H., Kartamihardja, A. H. S., & Hernowo, B. S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.8791 · Cited by 9
Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells
Kuracha, M. R., Govindarajan, V., Loggie, B. W., Tobi, M., & McVicker, B. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512331 · Cited by 9
SREBPs as the potential target for solving the polypharmacy dilemma
Wang, X., Chen, Y., Meng, H., & Meng, F. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2023.1272540 · Cited by 10
A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.
Lawal, B., Lo, W., Mokgautsi, N., Sumitra, M. R., Khedkar, H., Wu, A. T. H., & Huang, H. (2021) · PubMed Central · Cited by 9
Overexpression of E74‑like transformation‑specific transcription factor 3 promotes cellular proliferation and predicts poor prognosis in ovarian cancer
Liu, Y., Wang, S., Zhou, R., Li, W., & Zhang, G. (2021) · Oncology Letters · doi:10.3892/ol.2021.12971 · Cited by 9
Rictor Activates Cav 1 Through the Akt Signaling Pathway to Inhibit the Apoptosis of Gastric Cancer Cells
Cao, R., Min, L., Liu, S., Tian, R., Jiang, H., Liu, J., Shao, L., Cheng, R., Zhu, S., Guo, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641453 · Cited by 9
High Expression of PAMR1 Predicts Favorable Prognosis and Inhibits Proliferation, Invasion, and Migration in Cervical Cancer
Yang, R., Ma, M., Yu, S., Li, X., Zhang, J., & Wu, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.742017 · Cited by 9
A multi-omics study of the anti-cancer effect of a ferulic acid derivative FA-30
Wang, D., Guo, D., Tang, Y., Qi, M., Fang, J., Zhang, Y., Chai, Y., Cao, Y. W., & Lv, D. (2022) · Molecular Omics · doi:10.1039/d2mo00025c · Cited by 9
The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTOR signaling pathway in chronic myeloid leukemia
Liu, X., Wang, Y., Wang, J., Quan, J.-K., Li, X., & Guan, K.-P. (2023) · Hematology · doi:10.1080/16078454.2022.2161201 · Cited by 9
A chlorin e6 derivative-mediated photodynamic therapy inhibits cutaneous squamous cell carcinoma cell proliferation via Akt/mTOR signaling pathway
Tao, H., Zhang, H., Xu, D., Yan, G., Wu, Y., Zhang, G., Zeng, Q., & Wang, X. (2023) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2023.103332 · Cited by 9
Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer
Chen, H., Zhang, L., Zuo, M., Lou, X., Liu, B., & Fu, T. (2023) · Aging · doi:10.18632/aging.204564 · Cited by 8
Proteomic Markers for Mechanobiological Properties of Metastatic Cancer Cells
Leonov, S., Inyang, O., Achkasov, K., Bogdan, E., Kontareva, E., Chen, Y.-H., Fu, Y., Osipov, A., Pustovalova, M., & Merkher, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054773 · Cited by 8
A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy
Mandal, S. K., & Samanta, S. K. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673327425240815065221 · Cited by 8
Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating Oncological Disorders
Khanal, S., Pillai, M., Bhuia, M. S., Islam, M. T., Sharma, O., Verma, R., Nepovimová, E., Kuča, K., Kumar, D., & Chowdhury, R. (2025) · Phytotherapy Research · doi:10.1002/ptr.70051 · Cited by 7
Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions
Leiphrakpam, P. D., Batra, R., Tenner, L. L., & Are, C. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl39100 · Cited by 10
Circ_0028007 Aggravates the Malignancy of Nasopharyngeal Carcinoma by Regulating miR-656-3p/ELF2 Axis
Ma, X., & Li, Y. (2022) · Biochemical Genetics · doi:10.1007/s10528-022-10205-8 · Cited by 8
RIOK3 promotes mTORC1 activation by facilitating SLC7A2-mediated arginine uptake in pancreatic ductal adenocarcinoma
Qin, H., Sun, R., Guo, X., Fang, L., Xu, M., Teng, Y., Ning, Z., Wang, A., & Liu, J. (2023) · Aging · doi:10.18632/aging.204528 · Cited by 8
How is the AKT/mTOR pathway involved in cell migration and invasion?
XU, J., HAO, S., HAN, K., YANG, W., & Deng, H. X. (2023) · Biocell · doi:10.32604/biocell.2023.026618 · Cited by 8
Azaphilones with anti-colon cancer activities from the plant endophytic fungus Talaromyces primulinus WZ-883
Gong, Y., Li, X., Shi, L.-Y., Feng, L., Wang, J.-W., Tan, N., & Wang, Z. (2023) · Phytochemistry Letters · doi:10.1016/j.phytol.2023.08.006 · Cited by 8
Duloxetine enhances the sensitivity of non-small cell lung cancer cells to EGFR inhibitors by REDD1-induced mTORC1/S6K1 suppression
Jang, S. (2024) · American Journal of Cancer Research · doi:10.62347/wmqv6643 · Cited by 8
Targeting protein synthesis pathways in MYC-amplified medulloblastoma
Kumar, D., Kanchan, R. K., & Chaturvedi, N. K. (2025) · Discover Oncology · doi:10.1007/s12672-025-01761-7 · Cited by 9
WNK2 Inhibits Autophagic Flux in Human Glioblastoma Cell Line
Alves, A. L. V., Costa, Â. M., Martinho, O., da Silva, V. D., Jordan, P., Silva, V. A. O., & Reis, R. M. (2020) · Cells · doi:10.3390/cells9020485 · Cited by 8
miR‐18a expression in basal cell carcinoma and regulatory mechanism on autophagy through mTOR pathway
Mi, X., Lai, K., Yan, L., Xie, S., Qiu, X., Xiao, S., & Wei, S. (2020) · Clinical and Experimental Dermatology · doi:10.1111/ced.14322 · Cited by 8
Cytotoxicity of oleanane type triterpene from leaf extract of Pterospermum acerifolium (in vitro) and theoretical investigation of inhibitory signaling pathway
Rehan, M., Shafiullah, & Sultanat (2020) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2020.09.004 · Cited by 8
Synergistic effects of Rapamycin and Fluorouracil to treat a gastric tumor in a PTEN conditional deletion mouse model
Zhu, C., Peng, S., Cui, L., Cao, W., Zhang, L., Zhao, Z., Li, J. X., Zhang, T., Guo, J., & Pang, C. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01229-x · Cited by 8
Autophagy Inhibition Enhances the Anti-Tumor Activity of Methylseleninic Acid in Cisplatin-Resistance Human Lung Adenocarcinoma Cells
Xin, M., Gao, Q., Xiang, X., Xu, J., Jiao, Y., Li, X., Zhang, X., & Jia, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.890974 · Cited by 8
Exploring biomarkers for prognosis and neoadjuvant chemosensitivity in rectal cancer: Multi-omics and ctDNA sequencing collaboration
Jiang, X., Zhang, B., Du, F., Guo, J., Wang, D., Li, Y.-E., Deng, S.-H., Cui, B., & Liu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1013828 · Cited by 8
Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review
Barbosa, M. G., Garcia, G. T., Sarin, L. M., & Jackowski, A. P. (2022) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-2876 · Cited by 9
PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer
Özcan, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1216438 · Cited by 8
The HACE1 E3 ligase mediates RAC1‐dependent control of mTOR signaling complexes
Turgu, B., El-Naggar, A. M., Kögler, M., Tortola, L., Zhang, H., Hassan, M., Lizardo, M. M., Kung, S. H. Y., Lam, W. L., Penninger, J. M., et al. (2023) · EMBO Reports · doi:10.15252/embr.202356815 · Cited by 8
Maackiain suppresses the development of cervical cancer via AMPK priming autophagy
He, J., Xiang, L., Zhu, T., Wang, H., Huang, Y., Li, H., Miao, C., Zhuang, Y., & Cao, Y. (2023) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad100 · Cited by 8
Integrated analysis identifies a novel lncRNA prognostic signature associated with aerobic glycolysis and hub pathways in breast cancer
Li, Z., Zheng, J., Feng, Y., Li, Y., Liang, Y., Liu, Y., Wang, X., & Yang, Q. (2021) · Cancer Medicine · doi:10.1002/cam4.4291 · Cited by 8
Expression of Ribosomal Protein S6 Kinase (S6K1) Isoforms in Different Types of Papillary Thyroid Carcinoma
Garifulin, O. M., Filonenko, V. V., Bdzhola, A. V., PUSHKAREV, V. V., Zinych, P. P., Pushkarev, V. M., Guda, B. B., Ковзун, О. І., & Tronko, M. D. (2023) · Cytology and Genetics · doi:10.3103/s0095452723040059 · Cited by 7
Adipose tissue-derived stem cells, in vivo and in vitro models for metabolic diseases
Navarro-Perez, J., & Carobbio, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116108 · Cited by 10
Deciphering potential molecular mechanisms in clear cell renal cell carcinoma based on the ubiquitin‐conjugating enzyme E2 related genes: Identifying UBE2C correlates to infiltration of regulatory T cells
Feng, X., Wang, Z., Cen, M., Zheng, Z., Wang, B., Zhao, Z., Zhong, Z., Zou, Y., Lv, Q., Li, S., et al. (2024) · BioFactors · doi:10.1002/biof.2143 · Cited by 7
BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake
Mancini, C., Menegazzi, G., Peppicelli, S., Versienti, G., Guasti, D., Pieraccini, G., Rovida, E., Lulli, M., Papucci, L., Sbarba, P. D., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03805-y · Cited by 8
Crosstalk of glutamine metabolism between cancer-associated fibroblasts and cancer cells
Chen, T., Xu, Y., Yang, F., Pan, Y., Ji, N., Li, J., Zeng, X. Y., Chen, Q., Jiang, L., & Shen, Y. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111874 · Cited by 9
Role of exosomal non‑coding RNAs in cancer‑associated fibroblast‑mediated therapy resistance (Review)
Li, J., Huang, Y. Y., Fu, L., Shi, M., Hu, G., Du, F., Wang, Z., Xiao, Y., Zhang, Y., & Li, Y. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5774 · Cited by 9
ATF5 inhibits autophagy and the Wnt/β-catenin pathway by upregulating mTOR to suppress the stemness of liver cancer stem cells
Jiang, J., Li, X., Zhang, H., Liu, W., Hu, C., & Hu, Z. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103094 · Cited by 7
The Interplay of Aging and Cancer: Mechanisms, Implications, and Therapeutic Strategies
Wang, L., Luo, Y., Chen, X., Wang, Y., & Zhang, Y. (2025) · MedComm – Oncology · doi:10.1002/mog2.70041 · Cited by 8
Protocadherin gamma C3: a new player in regulating vascular barrier function
Burek, M., Kaupp, V., Blecharz-Lang, K. G., Dilling, C., & Meybohm, P. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.343896 · Cited by 7
Natural isoflavone glabridin targets PI3Kγ as an adjuvant to increase the sensitivity of MDA-MB-231 to tamoxifen and DU145 to paclitaxel
Lin, H., Ai, D., Liu, Q., Xl, W., Chen, Q., Hong, Z., Tao, Y., Gao, J., & Wang, L. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106426 · Cited by 8
Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma
Lin, P., Cheng, W., Qi, X., Zhang, P., Xiong, J., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031555 · Cited by 7
mTOR inhibition by AZD2014 alleviates BCR::ABL1 independent imatinib resistance through enhancing autophagy in CML resistant cells
He, W. (2024) · American Journal of Cancer Research · doi:10.62347/rwlj3990 · Cited by 7
COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC
Zhang, J., Wang, X., Li, G., He, J., Lu, Z., Yang, Y., Jiang, Y., Jiang, L., Li, F., & Liu, J. (2021) · BioMed Research International · doi:10.1155/2021/6648078 · Cited by 7
Putative dual inhibitors of mTOR and RET kinase from natural products: Pharmacophore-based hierarchical virtual screening
Parate, S., Kumar, V., Hong, J. C., & Lee, K. W. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.118562 · Cited by 7
Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma
Lin, R. J., Xu, Y., Xie, S., Zhang, Y., Wang, H., Yi, G., Huang, G., Ni, B., Song, H., Wang, Z., et al. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-03964-2 · Cited by 7
Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis
Yu, C.-C., Wu, Y., Hu, K., & Zhang, S. (2022) · BioMed Research International · doi:10.1155/2022/4123622 · Cited by 7
Artemin Promotes the Migration and Invasion of Cervical Cancer Cells through AKT/mTORC1 Signaling
Zhu, M., Zhou, L., Fu, J., Wang, Y., Xu, X., Wu, J., Kong, X., Li, J., Zhou, Z., & Zhou, H. (2022) · Journal of Oncology · doi:10.1155/2022/3332485 · Cited by 7
Heteronuclear Ru(II)-Re(I) complexes as potential photodynamic anticancer agents with anti-metastatic and anti-angiogenic activities
Ma, X.-R., Lu, J., Huang, B., Lu, X.-Y., Li, R., & Ye, R. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2022.112090 · Cited by 7
Silencing PKM2 Attenuates Brain Injury Induced by Status Epilepticus by Inhibiting the AKT/mTOR Pathway and the NLRP3 Inflammasome
Cui, X., Jia, R., Zhao, R., Ma, N., & Jiang, F. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04023-6 · Cited by 7
Rictor—A Mediator of Progression and Metastasis in Lung Cancer
Szalai, F., Sztankovics, D., Krencz, I., Moldvai, D., Pápay, J., Sebestyén, A. R., & Khoór, A. (2024) · Cancers · doi:10.3390/cancers16030543 · Cited by 7
Design, optimization, characterization, and in vitro evaluation of metformin-loaded liposomes for triple negative breast cancer treatment
Vozgirdaite, D., Hervé-Aubert, K., Uzbekov, R. E., Chourpa, I., & Allard-Vannier, É. (2024) · Journal of Liposome Research · doi:10.1080/08982104.2024.2321528 · Cited by 7
Defensins: Exploring Their Opposing Roles in Colorectal Cancer Progression
Sabit, H., Pawlik, T. M., Abdel-Ghany, S. E., & Arneth, B. M. (2024) · Cancers · doi:10.3390/cancers16152622 · Cited by 7
Akt/mTOR Activation in Lung Cancer Tumorigenic Regulators and Their Potential Value as Biomarkers
Sousa, C., Lima, B. S., & Videira, M. (2022) · Onco · doi:10.3390/onco2010004 · Cited by 7
Fasting-induced RNF152 resensitizes gallbladder cancer cells to gemcitabine by inhibiting mTORC1-mediated glycolysis
Tao, Y., Gong, Z., Shen, S., Ding, Y., Zan, R., Zheng, B., Sun, W., Ma, C., Shu, M., Xiao, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109659 · Cited by 6
MTOR maintains endothelial cell integrity to limit lung vascular injury
Millar, M. W., Najar, R. A., Slavin, S. A., Shadab, M., Tahir, I., Mahamed, Z., Lin, X., Abe, J., Wright, T. W., Dean, D. A., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107952 · Cited by 7
Small-molecule inhibitor of C‑terminal HSP90 dimerization modulates autophagy and functions synergistically with mTOR inhibition to kill cisplatin-resistant cancer cells
David, C., Sun, Y., Woloschin, V., Vogt, M., Dienstbier, N., Friedrich, A., Krings, K. S., Schlütermann, D., Berning, L., Lungerich, B., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08330-4 · Cited by 6
mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models
Lisi, L., Pizzoferrato, M., Ciotti, G. M. P., Martire, M., & Navarra, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129834 · Cited by 6
The role of AMPK in pancreatic cancer: from carcinogenesis to treatment
Nejad, S. S., Razi, S., & Rezaei, N. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03572-8 · Cited by 6
Cancer-driving mutations and variants of components of the membrane trafficking core machinery
Yong, C. Q. Y., & Tang, B. L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118662 · Cited by 6
HISMD: A Novel Immune Subtyping System for HNSCC
Yang, D., Wu, Y., Wan, Z., Xu, Z., Li, W.-G., Yuan, P., Shang, Q., Peng, J., Tao, L., Chen, Q., et al. (2022) · Journal of Dental Research · doi:10.1177/00220345221134605 · Cited by 6
mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance
Bu, C., Zhao, L., Wang, L., Yu, Z., & Zhou, J. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.029309 · Cited by 7
Identification of ferroptosis-related proteins in ameloblastoma based on proteomics analysis
Li, H., Ma, X., Yang, R., Mei, S., Zhang, X., & Li, X. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05412-8 · Cited by 6
A Novel Gene Pair CSTF2/DPE2A Impacts Prognosis and Cell Cycle of Hepatocellular Carcinoma
Huang, Y., Xu, J., Xie, C., Liao, Y., Lin, R., Zeng, Y., & Yu, F. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s413935 · Cited by 6
Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma
Codina‐Martínez, H., Lorenzo‐Guerra, S. L., Cabal, V. N., García‐Marín, R., Suárez–Fernández, L., Vivanco, B., Sánchez‐Fernández, P., López, F., Llorente, J. L., & Hermsen, M. A. J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015110 · Cited by 6
TRIM34 suppresses non-small-cell lung carcinoma via inducing mTORC1-dependent glucose utilization and promoting cellular death
Zhang, P., Chen, Z., Li, J., Mao, H., & Hu, Y. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.109925 · Cited by 6
ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling
Da, X., GE, H., SHI, J., Zhu, C., WANG, G., Fang, Y., & XU, J. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.045433 · Cited by 6
The role of CD98 heavy chain in cancer development.
Park, E., Kim, H., Yoon, S.-H., & Jang, B. G. (2024) · PubMed · doi:10.14670/hh-18-749 · Cited by 6
Correlation between Fatty Acid Transport Proteins and Phosphoinositide 3-Kinase Pathway in Breast Cancer
Acharya, R., Kumari, S., Shetty, S. S., Shetty, A. S., Monteiro, F., & Roopashree, P. G. (2024) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_125_24 · Cited by 6
Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer
Wang, C., Aikemu, B., Shao, Y., Zhang, S., Yang, G., Hong, H., Huang, L., Jia, H., Yang, X. J., Zheng, M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09901-w · Cited by 6
Integrated characterization and validation of the prognostic significance of microRNA-200s in colorectal cancer
Peng, Q., Cheng, M. Y., Li, T., Chen, X., Shen, Y., Zhu, Y., & Xu, B. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1142-1 · Cited by 6
Gut microbiota drives cancer evolution and therapy resistance
Min, S., Zhang, Y., Zhang, H., & Liu, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02564-8 · Cited by 8
Comprehensive evaluation of microRNA-10b in digestive system cancers reveals prognostic implication and signaling pathways associated with tumor progression
Shen, Y., Dai, X., Chen, H., Zhai, S., Peng, Q., Cai, S., Zhu, Y., Huan, J., & Shen, Y. (2021) · Journal of Cancer · doi:10.7150/jca.51303 · Cited by 5
RagC GTPase regulates mTOR to promote chemoresistance in senescence-like HepG2 cells
Jiang, W., Ou, Z., Zhu, Q., Yao, Y., & Zai, H. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.949737 · Cited by 5
DEPTOR as a novel prognostic marker inhibits the proliferation via deactivating mTOR signaling pathway in gastric cancer cells
Ma, G., Sun, Y., Cai, F., Zhang, M., Liang, H., Deng, J., Zhang, R., & Zhang, L. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113598 · Cited by 5
Targeted small molecule therapy and inhibitors for lymphoma
Wang, Z., Zheng, X., Rao, G., & Zheng, Q. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2359893 · Cited by 5
The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway
Zhu, Y.-H., Jia, Q.-Y., Yao, H., Duan, Z., Ma, X.-S.-Y., Zheng, J.-H., Yin, Y., Liu, W., Zhang, J., Hua, R., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03440-z · Cited by 5
EIF2S2 transcriptionally upregulates HIF1α to promote gastric cancer progression via activating PI3K/AKT/mTOR pathway
Wang, Z., Zhang, Y., Xue, Y., Huang, W., & Zhang, H. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae043 · Cited by 5
Translational control in the naked mole-rat as a model highly resistant to cancer
Maldonado, G., & Hernández, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188455 · Cited by 5

Authors: Murugan, A. K.
Affiliations: King Faisal Specialist Hospital & Research Centre (SA)
Corresponding author: Murugan, Avaniyapuram Kannan
ORCID: Murugan, Avaniyapuram Kannan
Venue: Seminars in Cancer Biology
Publisher: Elsevier BV
Published: 2019-12
Volume: 59
Pages: 92-111
ISSN: 1044-579X (ISSN-L)
DOI: 10.1016/j.semcancer.2019.07.003
OpenAlex: W2969086321
Cited by: 483
References: 234
Citations by year: 2026: 25 · 2025: 57 · 2024: 84 · 2023: 84 · 2022: 120 · 2021: 74 · 2020: 31 · 2019: 7
FWCI: 5.13
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Seminars in Cancer Biology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords: mTOR, cancer, metastasis, drug resistance, mTOR inhibitors, somatic mutations, gene amplification, cell growth signaling, autophagy, precision medicine, immunosuppressants
MeSH terms: Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Animals, Disease Susceptibility, Enzyme Activation, Humans, Mutation, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Biomarkers, Tumor, Signal Transduction, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases, Molecular Targeted Therapy, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

mTOR: Role in cancer, metastasis and drug resistance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks